149 related articles for article (PubMed ID: 35858230)
1. Association of Ultrasound Features in Uveal Melanoma With Metastatic Risk as Defined by Preferentially Expressed Antigen in Melanoma Status.
Rusakevich AM; Schefler AC; Zhou B; Brown A; Robe C; Bretana ME
Ophthalmic Surg Lasers Imaging Retina; 2022 Jul; 53(7):374-378. PubMed ID: 35858230
[TBL] [Abstract][Full Text] [Related]
2. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
Cai L; Paez-Escamilla M; Walter SD; Tarlan B; Decatur CL; Perez BM; Harbour JW
Am J Ophthalmol; 2018 Nov; 195():154-160. PubMed ID: 30092184
[TBL] [Abstract][Full Text] [Related]
5. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
6. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
7. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.
Nguyen BT; Kim RS; Bretana ME; Kegley E; Schefler AC
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):421-427. PubMed ID: 29185101
[TBL] [Abstract][Full Text] [Related]
8. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
10. Independent Prognostic Significance of Gene Expression Profile Class and Largest Basal Diameter of Posterior Uveal Melanomas.
Corrêa ZM; Augsburger JJ
Am J Ophthalmol; 2016 Feb; 162():20-27.e1. PubMed ID: 26596399
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S
Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437
[TBL] [Abstract][Full Text] [Related]
13. Correlation of PRAME immunohistochemistry with PRAME status on gene expression profiling in enucleated uveal melanoma.
Vizcaino MA; Dalvin LA; Salomao DR
Can J Ophthalmol; 2024 Jun; 59(3):e279-e282. PubMed ID: 38114062
[No Abstract] [Full Text] [Related]
14. Intrinsic disorder in PRAME and its role in uveal melanoma.
Antonietti M; Gonzalez DJT; Djulbegovic M; Dayhoff GW; Uversky VN; Shields CL; Karp CL
Cell Commun Signal; 2023 Aug; 21(1):222. PubMed ID: 37626310
[TBL] [Abstract][Full Text] [Related]
15. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
17. New concepts in the molecular understanding of uveal melanoma.
Reichstein D
Curr Opin Ophthalmol; 2017 May; 28(3):219-227. PubMed ID: 28257297
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.
Walter SD; Chao DL; Feuer W; Schiffman J; Char DH; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):734-40. PubMed ID: 27123792
[TBL] [Abstract][Full Text] [Related]
19. Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.
Cazzato G; Mangialardi K; Falcicchio G; Colagrande A; Ingravallo G; Arezzo F; Giliberti G; Trilli I; Loizzi V; Lettini T; Scarcella S; Annese T; Parente P; Lupo C; Casatta N; Maiorano E; Cormio G; Resta L; Ribatti D
Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328098
[TBL] [Abstract][Full Text] [Related]
20. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
Cassalia F; Danese A; Tudurachi I; Federico S; Zambello A; Guidotti A; Franceschin L; Bolzon A; Naldi L; Belloni Fortina A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]